Joseph Frattaroli
CFO
CFO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $354,868 | $370,383 |
| 2023 | Inhibikase Therapeutics, Inc. (IKT) | Former Chief Financial Officer | $408,333 | $579,964 |
| 2022 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Former Chief Financial Officer | $395,833 | $574,765 |
| 2021 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $375,000 | $487,500 |
| 2020 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $300,000 | $1,642,220 |
| 2019 | Inhibikase Therapeutics, Inc. (IKT) | C.P.A. Chief Financial Officer | $300,000 | $300,000 |
Executive changes
Earnings-call appearances
-
Inhibikase Therapeutics, Inc. Q3 FY2023 Earnings Call2023-09-30
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q2 FY2023 Earnings Call2023-06-30
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q1 FY2023 Earnings Call2023-03-31
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q2 FY2022 Earnings Call2022-06-30
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q1 FY2022 Earnings Call2022-03-31
Inhibikase Therapeutics, Inc. (IKT)
-
Inhibikase Therapeutics, Inc. Q4 FY2021 Earnings Call2021-12-31
Inhibikase Therapeutics, Inc. (IKT)